OABI
Omniab, Inc. Health Care Services-Commercial Physical & Biological Research Russell 3000
$5.11Close
$737.4MMarket cap
$1.36 – $5.2852-week range
Jan 28, 2027Next report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
- Near its high 3% below its 52-week high
- Tight base near its pivot pullbacks 28% → 17%; 0.4% above its $5.09 pivot
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
3%
1wk
up 9.7%
price change
1mo
up 3.0%
price change
12-month return
up 243%
market up 11% ·
its own up 237%
F-score
—
— Not assessed
Altman Z″
6.00
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.8×
price / book
Earnings yield
down 9.7%
EBIT / enterprise value
Cheaper than
26%
of the market · expensive
Revenue growth
down 29%
year on year
EPS growth
—
latest quarter
Sales growth
up 78%
latest quarter · -166 pts
ROE
down 23%
return on equity
Free cash margin
down 198%
-$37.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.0%
$0.36 a day · 2×ATR $4.40
RS
99 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.4×
vs 50-day average
Up/down volume
1.09
50 sessions
Implied move
—
no scheduled report
Contractions
2
28% → 17%
Pivot
$5.09
0.4% above
Volume dry-up
1.1×
10 vs 50 sessions
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 18.7% over the year, from 122m to 144m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 29.3% over the year, from $26.4M to $18.7M.
Last reported
Oct 30, 2026
Results reaction
Oct 30, 2026-1% vs market2 sessions after results
Financials
- Net -347%
- Free cash -198%
- Cash
- Long-term debt
| FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|
| Revenue | $34.7M | $59.1M | $34.2M | $26.4M | $18.7M |
| Operating income | -$35.6M | -$26.6M | -$69.4M | -$74.5M | -$69.0M |
| Net income | -$27.0M | -$22.3M | -$50.6M | -$62.0M | -$64.8M |
| Net margin | -78% | -38% | -148% | -235% | -347% |
| Earnings per share | -$0.33 | -$0.26 | -$0.51 | -$0.61 | -$0.57 |
| Free cash flow | -$9.7M | -$20.8M | $703,000 | -$41.5M | -$37.0M |
| Free cash margin | -28% | -35% | 2% | -157% | -198% |
| Cash | $0 | $33.4M | $16.4M | $27.6M | $25.5M |
| Shareholders' equity | $234.3M | $341.4M | $314.6M | $287.6M | $267.0M |
| Shares outstanding | 0 | 115.22m | 116.86m | 121.60m | 144.31m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 30, 2026 | Quarterly ↗ | Sep 30, 2026 | 30d |
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 4, 2026 | Annual ↗ | Dec 31, 2025 | 63d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 18, 2025 | Annual ↗ | Dec 31, 2024 | 77d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 25, 2024 | Annual ↗ | Dec 31, 2023 | 85d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 30, 2026 | Results ↗ |
| Aug 6, 2026 | Results ↗ |
| Jul 13, 2026 | Director or officer change ↗ |
| Jun 18, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 4, 2026 | Results ↗ |
| Jan 30, 2026 | Charter or bylaws ↗ |
| Nov 4, 2025 | Results ↗ |
| Aug 25, 2025 | Material agreement · Unregistered share sale · Regulation FD ↗ |
| Aug 6, 2025 | Results ↗ |
| Jun 18, 2025 | Shareholder vote ↗ |
| May 8, 2025 | Results ↗ |